High Marks for CAR T-Cell Therapy in MCL

]]>(MedPage Today) -- More than 90% of patients with advanced mantle cell lymphoma (MCL) responded to the CD19-targeted chimeric antigen receptor (CAR) T-cell therapy KTE-X19, and a majority had no disease progression at 12 months, a multicenter trial...